$LAHO Goldman Sachs highlighted..$12 billion private biotech startup that wants to regenerate hair, skin, bones, and joints, and Unity Biotechnology, which is working on treatments that act on senescent cells.
Money is pouring in to a hot new area of science that could change the way we think about aging
.."We believe companies backed by academic pioneers ... or those with novel platforms ... are likely to garner the largest investments and valuations," the report said.
Venture capitalists..betting big on..regenerative medicine
..Until the myth of the fountain of youth proves true, regenerative medicine is the best hope we’ve got for fixing failed body parts and, as a result, living longer.
..scientists seek funding from public sources too, of course. At the University of Washington’s Institute for Stem Cell and Regenerative Medicine, for example, researchers are manipulating stem cells to heal and restore the function in hearts, eyes, kidneys and other tissues,
Researchers Discover Stem Cells..for Growing and Healing Bone
..“This is the first direct evidence that bone contains multiple populations of stem cells with different functions and anatomic locations,” Dr. Greenblatt said. “Until now, drug discovery has involved looking at a mixed bag of stem cells from inside and outside bone. We believe that many therapies that build bone to treat osteoporosis may work by activating these periosteal stem cells. Working directly with this exact cell type will be essential for developing new targeted drugs for osteoporosis and healing bone injuries.”
The injection of PRP is a procedure and therefore not regulated by the US Food and Drug Administration (FDA). The FDA has approved multiple devices used to separate whole blood into PRP through the 510(k) process.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.